Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label phase 1 study of ABBV-621 alone and in combination in previously treated malignancies
NL-OMON49604Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of eftozanermin in Nonhematologic neoplasms, acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and 3 more (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 1 more. Started Aug 2017; status: active, not recruiting.
02
Drugs
eftozanermin
03
Conditions
Nonhematologic neoplasmsacute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON49604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49604.